Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

Starting in 2025, the Eylea franchise as a whole began to decline due to competitive pressure from long-acting Vabysmo, which competes with Eylea HD, and Pabvlu, a biosimilar version of the original ...

Regeneron does not undertake any obligation ... With physician and patient awareness building and strong reimbursement established, the COPD launch has outperformed all other Dupixent indication ...

Explore Regeneron's Q1 2025 earnings with updates on Dupixent growth, EYLEA challenges, FDA hurdles, and upcoming approvals.

Regeneron has formed a corporate venture capital ... return and to get closer to organisations that may provide pipeline-building opportunities. Regeneron’s fund will be independently managed ...

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, ...

Regeneron Pharmaceuticals ... The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month ...

Ralph Lauren has shelled out $132M for the retail condo units at 109 Prince St. in SoHo, public records show. The deal ends a challenge brought by LVMH, which was eyeing the space as it searched for a ...

U.S. Treasuries rallied on Monday in advance, with a dour manufacturing survey from the Dallas Federal Reserve for April ...

While pharma manufacturing deals in the US increased, large cuts to research and regulatory agencies increased concerns for ...